Clinical Utility of Ivosidenib in the Treatment of IDH1|Mutant ...

Ivosidenib Treatment for R/R AML in Patients With an IDH1 Mutation

Ivosidenib, a first-in-class, oral, small molecule inhibitor of mutant IDH1, is approved by the FDA for mIDH1 relapsed/refractory AML and newly ...

Ivosidenib for the treatment of relapsed or refractory acute myeloid ...

... mutation in July 2018 and for unfit AML patients with IDH1 mutation as first line treatment in May 2019. Expert commentary. Ivosidenib induces impressive ...

Ivosidenib in Treating Patients With Advanced Solid Tumors ...

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial). a ...

Ivosidenib Provides Prolonged Progression-Free Survival

Patients with advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 (IDH1) mutation showed clinical benefit and improved progression- ...

IDIOME: ivosidenib in IDH1 mutant MDS - VJHemOnc

Ivosidenib, a small molecule inhibitor of mutant IDH1, is FDA approved for the treatment of patients with relapsed ... use this site you are ...

Ivosidenib approved as first-line treatment for AML with IDH1 mutation

Ivosidenib has been granted approval by the U.S. FDA as first-line treatment for newly diagnosed AML with IDH1 mutation.

TIBSOVO® (ivosidenib tablets)

Treatment for acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) & cholangiocarcinoma (CCA). See Full Prescribing Information & Boxed Warning.

Expanding the Use of Tibsovo in AML - HealthTree

Dr. Eytan Stein will join us to discuss the IDH mutations, treatment options and the recent approval of Tibsovo (ivosidenib) in combination ...

IDH1 Mutations in AML | TIBSOVO® (ivosidenib tablets) MOA

Learn about the need for IDH1 testing before prescribing an AML treatment ... Test for mIDH1 before prescribing to optimize treatment. Both the NCCN Clinical ...

Ivosidenib Extends Survival in Patients with Cholangiocarcinoma ...

Based on these results, on March 1, 2021, a New Drug Application for ivosidenib was submitted to the FDA for the treatment of patients with CCA and IDH1 ...

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 ...

Preliminary data from phase 1 clinical trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable ...

FDA Approves Ivosidenib Tablets for IDH1-Mutant ...

The FDA has approved ivosidenib Tablets (Tibsovo) for the treatment of patients with IDH1-mutant cholangiocarcinoma, as detected by an FDA approved test.

Cost-effectiveness of ivosidenib versus chemotherapy for previously ...

This study aimed to assess ivosidenib cost-effectiveness as a subsequent-line treatment for advanced ICC with IDH1 mutations in comparison with ...

Press Release Details - Agios Pharmaceuticals, Inc.

TIBSOVO® (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid ...

Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of ...

The IDH1 inhibitor, olutasidenib, demonstrated encouraging safety and clinical benefits as monotherapy in patients with relapsed or refractory (R/R) mIDH1 AML.

Final Overall Survival Efficacy Results of Ivosidenib for Patients with ...

Patients receiving ivosidenib reported no apparent decline in quality of life compared with placebo. Conclusions and Relevance: This randomized clinical trial ...

Clinical Implications of Isocitrate Dehydrogenase Mutations ... - MDPI

Recently, the Food and Drug Administration approved three mutant IDH (mIDH) inhibitors for the treatment of AML. However, the use of mIDH inhibitors in ...

First targeted treatment for low-grade brain tumors on the horizon

Researchers compared this drug, ivosidenib, to vorasidenib, which inhibits both the IDH1 and IDH2 mutations and is designed for better uptake ...

Acute myeloid leukemia: Management of medically unfit adults

IDH1-mutated AML — For patients with mutated IDH1, we recommend treatment with azacitidine plus ivosidenib, rather than an HMA alone (algorithm ...

Ivosidenib and Azacitidine Combination Shows Significant Clinical

Ivosidenib monotherapy is approved in the US for adults with relapsed or refractory IDH1-mutated AML or patients with newly diagnosed IDH1- ...